sign in sign up
<<
Home , Daclatasvir, Sofosbuvir

/ V C s , us. H C .

r t i e y c v h a e f r f i * f * , epatitis iginal o age (over eadac h eatment, * r s s e e t by ide e ,2, a hi ed anyw e v ugs 1 e or T m h h s

a ra eir T cv/ t out o h

fer e ation x . e Study iod of time l z e on h a o s t irin among e h ting dr with ence. Trials per w r linz l k e fects were h a a eceiv a per oup.org/h -figh c can be cur possib ith or r D tance to s i V

s e same as th e i w s n out Ribav s doses of th eople

. s C i , any P r and r ith e eth H ssociation for a longer R i ealth Organ w h

A . o H about w

e not th called adh en. but m ld s s in Cli r ealthier ith or r ican i r h e o

s w

cure rates did not dif r ent, i eatmentactiongr e tak ide 5%. r W e patients. t i daclatasv v

. Rat ually egimen for If people mis e a buv r en once daily ov h h 2 2 ent options r eatm T e e us ent. 2% p r ey ure e most common side ef king. osis osis osis osis osis s of age and older s of age and r a e tak h e th //www C /Sofos re o t eeting of Ame r 9-8 3% alence is < , v tp: ials -treatm odak. w t M Some copies ar e 7 9 90% h ugs th 8% 00% eatment-naïv medication—thi 8 year r In clinical trials, m: om 90% ation of sofosbuvir and daclatasv e optimal duration of sofosbuvir and 1 9 1 : t lth ca epatitis C tr o : h : : nnual y aclatasvi s e t a s s**: s**: s s**: , pe 3 pr e treatment depends on w e treatment depends CV dr r and name for e brand name e y h e H ugs fr h t v . oni or Sov o ar y e e r e people in tr /daclatasvir v y of D h r i u w e 68th A vailable fr o h ended for A

t . s, may need to tak and daclatasvir ar H 2 week 2 week 2 week 2 week 2 week esistant to HCV treatm ir is a fixed-dose combination of t combination ir is a fixed-dose s and may limit re + compensated cirrh 1 + compensated cirrh 24 week + compensated cirrh 1 1 1 1 h + compensated cirr + compensated cirrh e all your HCV e. ver been on h n and genot 1–6 w d tment Length an epatitis C dr more of th ecomm now r year fectiveness of th race/ethnicit ypes r e names Da k with yo e of sofosbuv d eness and safet esented at: l eatment. ave ne Trea n 5 December h e ef a Sofosbuvir 1 h a T 0 es billions of copies of itself.

v /daclatas T ed is to tak fectiv , :

ey CV treatment histor 2 . r o last for eatment naïv H C e . ed. sed? ld ef -related symptom eet. r session pr svir D at can stop h u o e copies may be r

a CV mak t ough th ) th vious oster H s mmended n clinical trials act Sh ype distribution is k P

esistance to tr e general population because th

, F n y 1). r r Sofosbuvi epatitis C genot epatitis C eal-w I ace. R hington, are not tr out liver ? .

s tasvir uar ge, gend d a ven th arin ith ey eir pre e a but it can als or r ; for sofosbuvir is Sovaldi and name elop w W ,

, ebr an in th

utatio ave resistance to one or v s g ; F ere genot 4 acla n–Reco m ach day a 9 h if th Ribav , us patients. E 1 e br d er th n osis r osis

i son can do to be cur h w onth h and tio ill de T V r rin

—and some of th m oup. w high nd gender in-free treatment regimens ar in-free treatment regimens , Sann K et al. 2 r aclatasvi h as not been establis va ugs may also be sold under th ugs may also e . a h ype, and th

nce? s), us a fosbuvir/dacla niza ually mild. osis osis osis osis a . ug resistance e t o dr rib oduce vir within e not cured h osis atasvir e vir Accessed 20 w up MW in countries h ( t Action Gr r

. Ribavir osis, or cir m so 7 October 20-2 anges (called s ug, h 1 e o o ar 8% 2% 2% 2% at th irin us genot 00% ave dr sbuvir/d th Org eek ; 20 9 9 1 9 9 g resista ey can be ma , no cirrh , no cirrh o ith cir s appear : : : : : er dr Sonder f w r/dacl e ts fr s s s s s w isk th ave ch reatment

eir vir . and daclatasvir) r /ribav eal T 2 under 65 year e sofosbu eas ance to repr e ing and suppor w th o fec uvi s H i s dru ype 5 ype 4, no cirrh ype 3 ype 6, no cirrh h ypes 1 and 2, no cirr h f ype 5 and 6 C i eets o b D sus t e rates in clinical trials ar buvir r s t t is so s can dis h r h for people with oved this regimen e ith anoth may h e rld osis, th a ch o r e v ecommended only u w patients o 2 week 2 week 2 week 2 week 2 week ost people wh monitor Liver genot factsh Iwamoto M, See als

ey e most important thing a per ugs

nd

r r C . . 1 Genot Genot 1 Genot Genot 1 1 Genot 1 h h W a cirrh 65 Side for Sof o d compensated cirr M food, for 1 Some people h **R How ar gets appr T * combination of th combination Wha (sofos low 2 fatigue, and nausea, us T 1 Wha The goal of (HCV) treatment is a cure (when there is no HCV in a person’s bloodstream at least 12 weeks at least person’s bloodstream in a is no HCV (when there is a cure treatment (HCV) C virus of hepatitis The goal ) is finished treatment after Does sofosbuvir/daclatasvir work with HIV drugs? Sofosbuvir/daclatasvir can be used with some HIV medicines, but doses may need to be adjusted from the standard 60 mg/day adult dose. Check with your doctor prior to taking sofosbuvir/daclatasvir regarding possible drug interactions. SOFOSBUVIR/DACLATASVIR Sofosbuvir/daclatasvir and other medications: Sofosbuvir/daclatasvir can be coadministered with opiate substitution medicines (e.g., buprenorphine or ) with no dose adjustments needed. Combining medications can increase or decrease drug levels (called drug-drug interactions). An increase can make side effects worse. A decrease can prevent a drug from working, putting people at risk for resistance or not being cured.

Sofosbuvir/daclatasvir should not be used in people taking the heart rhythm medication because sofosbuvir in combination with amiodarone can cause life-threatening heart problems. Do not take St. John’s wort herbal supplements with sofosbuvir/daclatasvir, and tell your doctor if you are taking statins or medications for cancer, seizures, bacterial infections or heartburn/acid reflux.

Talk with your health care provider before starting or stopping any medications, supplements, or herbal remedies.

Sofosbuvir/Daclatasvir and HIV Treatments (Antiretrovirals)

HIV protease inhibitors Atazanavir/ or atazanavir/cobicistat Reduce daclatasvir to 30 mg. (Reyataz) HIV integrase inhibitors Fixed-dose combination of elvitegravir, cobicistat, Reduce daclatasvir to 30 mg. , and tenofovir DF (Stribild) HIV non-nucleoside reverse transcriptase inhibitors (Sustiva, Atripla) Increase daclatasvir to 90 mg. Etravirine or nevirapine (Intelence, Viramune) Not recommended for use with sofosbuvir/daclatasvir. Tenofovir DF (Viread, Truvada, Atripla, Complera, No dose adjustment required. No known issue with TDF and Stribild) daclatasvir.

Storing sofosbuvir/daclatasvir: Keep sofosbuvir and daclatasvir at room temperature (below 30°C [86°F]).

Sofosbuvir/daclatasvir in people with kidney disease: Sofosbuvir/daclatasvir is not recommended for use in persons with severe renal impairment (chronic kidney failure grades 4 and 5).

Sofosbuvir/daclatasvir in people with : HCV treatment guidelines recommend that people with serious liver damage (Child-Pugh Class B or C) be treated by a specialist. Use of sofosbuvir/daclatasvir has been demonstrated to be generally safe and effective in people with cirrhosis (compensated and decompensated), but treatment duration may need to be adjusted based on the hepatitis C genotype. In addition, may be added to the treatment regimen.

Sofosbuvir/daclatasvir during pregnancy or nursing and in children: It is not known whether sofosbuvir/ daclatasvir causes harm to unborn babies or passes into breast milk. If you are pregnant or breast feeding, or planning for either, talk with your health care provider about the risks and benefits of HCV treatment. In animal studies of pregnant rats and rabbits, very high doses of sofosbuvir/daclatasvir caused birth defects, miscarriage, and maternal death. No harm was seen at lower doses.

Sofosbuvir/daclatasvir is currently being tested in children younger than 18 years old, but is not yet recommended for use in this age group.

Access to sofosbuvir/daclatasvir may be restricted by public and private payers. The criteria differ depending on the type of coverage and the state in which the coverage is issued. Support Path is Gilead’s patient assistance program for Sovaldi. People with private insurance may be eligible for assistance with copayments. Uninsured people may be eligible for medication at no charge. Information about Support Path is available by phone at 1-855-769-7284, Monday through Friday between 9:00 a.m. and 8:00 p.m. (Eastern Time), or online at https://www.gilead.com/purpose/medication-access/us-patient-access.

This fact sheet is current as of May 2019. Always check for updated information.